Bibliographie (2530)
Individual and community-level risk predictor for COVID-19 mortality in the US, with risk calculator
mercredi, 16 décembre 2020 12:42 Écrit par Zouhair SouissiIndividual and community-level risk for COVID-19 mortality in the United States – Nature Medicine Calculator: Covid-19 risk Commentary on Twitter New @NatureMedicine What is your individualized risk of dying from covid19?https://t.co/Bg61t3raVNhttps://t.co/tQGH0ilsmR (1.1X for me) pic.twitter.com/9pkwyCUAVw — Eric Topol (@EricTopol) December 11, 2020
The post Individual and community-level risk predictor for COVID-19 mortality in the US, with risk calculator appeared first on Links Medicus.
The coronavirus at 1: A year into the pandemic, what scientists know about how it spreads, infects, and sickens
mardi, 15 décembre 2020 05:48 Écrit par Zouhair SouissiThe coronavirus at 1: A year into the pandemic, what scientists know about how it spreads, infects, and sickens – STAT
The post The coronavirus at 1: A year into the pandemic, what scientists know about how it spreads, infects, and sickens appeared first on Links Medicus.
Critical review: “I’m upset about the RELAX trial” (study showing a lower PEEP strategy is noninferior to a higher PEEP strategy in ICU patients without ARDS)
mardi, 15 décembre 2020 05:48 Écrit par Zouhair SouissiI’m upset about the RELAX trial – PulmCrit Original study and commentaries: Randomized trial: Among patients in the ICU receiving invasive ventilation, a strategy with lower PEEP was noninferior to a strategy using higher PEEP Commentary from the author on Twitter RELAX trial?♂️PEEP 8 cm vs. lowest possible PEEP (as low as zero!) among […]
The post Critical review: “I’m upset about the RELAX trial” (study showing a lower PEEP strategy is noninferior to a higher PEEP strategy in ICU patients without ARDS) appeared first on Links Medicus.
![[Preprint] RECOVERY trial: Azithromycin does not improve outcomes in hospitalized patients with COVID-19](/media/k2/items/cache/37006d1f78a382af9c665654f8162781_M.jpg)
[Preprint] RECOVERY trial: Azithromycin does not improve outcomes in hospitalized patients with COVID-19
mardi, 15 décembre 2020 05:48 Écrit par Zouhair SouissiAzithromycin in Hospitalised Patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – medRxiv News release: RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19 Commentary: Expert reaction to preprint from the RECOVERY trial on the antibiotic azithromycin in patients hospitalised with COVID-19, reporting no benefit – Science Media Centre […]
The post [Preprint] RECOVERY trial: Azithromycin does not improve outcomes in hospitalized patients with COVID-19 appeared first on Links Medicus.
Consensus Guideline: Defining and managing COVID-19-associated pulmonary aspergillosis
mardi, 15 décembre 2020 05:48 Écrit par Zouhair SouissiDefining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance – The Lancet Infectious Diseases
The post Consensus Guideline: Defining and managing COVID-19-associated pulmonary aspergillosis appeared first on Links Medicus.
Randomized trial: Baricitinib plus remdesivir reduce recovery time in patients with COVID-19
lundi, 14 décembre 2020 01:55 Écrit par Zouhair SouissiBaricitinib plus Remdesivir for Hospitalized Adults with Covid-19 – New England Journal of Medicine Commentary: Baricitinib plus remdesivir shows promise for treating COVID-19 – NIH News Releases Commentary on Twitter Not sure how to interpret a trial for a drug plus Remdesivir vs Remdesivir alone when you don't know if Remdesivir works. @NEJM today […]
The post Randomized trial: Baricitinib plus remdesivir reduce recovery time in patients with COVID-19 appeared first on Links Medicus.
Randomized trial: Trimethoprim-Sulfamethoxazole does not benefit patients with moderate and severe idiopathic pulmonary fibrosis
lundi, 14 décembre 2020 00:31 Écrit par Zouhair SouissiEffect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial – JAMA Commentary: Idiopathic pulmonary fibrosis: Co-trimoxazole therapy did not prevent disease progression – MedicalResearch Commentary on Twitter In this RCT oral co-trimoxazole (TMP-SMX) did not reduce […]
The post Randomized trial: Trimethoprim-Sulfamethoxazole does not benefit patients with moderate and severe idiopathic pulmonary fibrosis appeared first on Links Medicus.
A systematic review of corticosteroid treatment for noncritically ill patients with COVID-19 – corticosteroid treatment is not recommended for patients with mild or moderate COVID-19
lundi, 14 décembre 2020 00:31 Écrit par Zouhair SouissiA systematic review of corticosteroid treatment for noncritically ill patients with COVID-19 – Scientific Reports
The post A systematic review of corticosteroid treatment for noncritically ill patients with COVID-19 – corticosteroid treatment is not recommended for patients with mild or moderate COVID-19 appeared first on Links Medicus.
Video: Coronavirus vaccine update with Anthony Fauci
lundi, 14 décembre 2020 00:31 Écrit par Zouhair SouissiCoronavirus Vaccine Update With Anthony Fauci – JAMA
The post Video: Coronavirus vaccine update with Anthony Fauci appeared first on Links Medicus.
Meta-analysis: Efficacy and harms of remdesivir for the treatment of COVID-19. “Until stronger evidence emerges, we cannot conclude that remdesivir is efficacious for treating COVID-19”.
lundi, 14 décembre 2020 00:31 Écrit par Zouhair SouissiEfficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis – PLOS One
The post Meta-analysis: Efficacy and harms of remdesivir for the treatment of COVID-19. “Until stronger evidence emerges, we cannot conclude that remdesivir is efficacious for treating COVID-19”. appeared first on Links Medicus.
